1	Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso:
2	interim results of a double-blind, randomised, controlled phase 2b trial in children
3	
4	Hamtandi M. Natama <sup>1,*</sup> , Jo Salkeld <sup>2,3,4,*</sup> , Athanase Somé <sup>1</sup> , Seyi Soremekun <sup>5</sup> , Salou Diallo <sup>1</sup> , Ousmane
5	Traoré <sup>1</sup> , Toussaint Rouamba <sup>1</sup> , Florence Ouédraogo <sup>1</sup> , Edouard Ouédraogo <sup>1</sup> , K. Carine Sonia Daboné <sup>1</sup> ,
6	Nadine A. Koné <sup>1</sup> , Z. Michael John Compaoré <sup>1</sup> , Miguel Kafando <sup>1</sup> , Massa dit Achille Bonko <sup>1</sup> , Fabé
7	Konaté <sup>1</sup> , Hermann Sorgho <sup>1</sup> , Carolyn M. Nielsen <sup>2,3</sup> , Dimitra Pipini <sup>2,3</sup> , Ababacar Diouf <sup>6</sup> , Lloyd D. W.
8	King <sup>2,3</sup> , Umesh Shaligram <sup>7</sup> , Carole A. Long <sup>6</sup> , Jee-Sun Cho <sup>2,3,4</sup> , Alison M. Lawrie <sup>4,8</sup> , Katherine Skinner <sup>2,3</sup> ,
9	Rachel Roberts <sup>2,3,4</sup> , Kazutoyo Miura <sup>6</sup> , John Bradley <sup>5</sup> , Sarah E. Silk <sup>2,3</sup> , Simon J. Draper <sup>2,3,8,†</sup> , Halidou
10	Tinto <sup>1,†</sup> , and Angela M. Minassian <sup>2,3,4,8,†</sup> .
11	
12	<sup>1</sup> Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
13	<sup>2</sup> Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.
14	<sup>3</sup> Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, Oxford,
15	OX1 3QU, UK.
16	<sup>4</sup> Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus,
17	Oxford, OX3 7LE, UK.
18	<sup>5</sup> London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
19	<sup>6</sup> Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
20	<sup>7</sup> Serum Institute of India Pvt. Ltd., Pune, India.
21	<sup>8</sup> NIHR Oxford Biomedical Research Centre, Oxford, UK.
22	* Joint first authors
23	<sup>†</sup> Joint senior authors
24	
25	Correspondence to: Angela M. Minassian, Department of Biochemistry, University of Oxford, Oxford,
26	OX1 3QU, UK ; angela.minassian@bioch.ox.ac.uk

#### Natama HM et al.

## 27 Abstract

#### 28 Background

Two pre-erythrocytic vaccines (R21/Matrix-M and RTS,S/AS01) are now approved for *P. falciparum* malaria. However, neither induces blood-stage immunity against parasites that breakthrough from the liver. RH5.1/Matrix-M, a blood-stage *P. falciparum* malaria vaccine candidate, was highly immunogenic in Tanzanian adults and children. We therefore assessed the safety and efficacy of RH5.1/Matrix-M in Burkinabe children.

#### 34 Methods

35 In this double-blind, randomised, controlled phase 2b trial, RH5.1/Matrix-M was given to children aged 36 5-17 months in Nanoro, Burkina Faso – a seasonal malaria transmission setting. Children received either 37 three intramuscular vaccinations with 10 µg RH5.1 protein with 50 µg Matrix-M adjuvant or three doses 38 of rabies control vaccine, Rabivax-S, given either in a delayed third dose (0-1-5-month) regimen (first cohort) or a 0-1-2-month regimen (second cohort). Vaccinations were completed part-way through the 39 40 malaria season. Children were randomly assigned 2:1 within each cohort to receive RH5.1/Matrix-M or 41 Rabivax-S. Participants were assigned according to a random allocation list generated by an independent 42 statistician using block randomisation with variable block sizes. Participants, their families, and the study 43 teams were masked to group allocation; only pharmacists who prepared the vaccines were unmasked. 44 Vaccine safety, immunogenicity, and efficacy were evaluated. Co-primary objectives assessed were: i) 45 safety and reactogenicity of RH5.1/Matrix-M, and ii) protective efficacy of RH5.1/Matrix-M against 46 clinical malaria from 14 days to 6 months post-third vaccination in the per-protocol population. This trial is registered with ClinicalTrials.gov (NCT05790889). 47 48 Findings

From 6<sup>th</sup> to 13<sup>th</sup> April and 3<sup>rd</sup> to 7<sup>th</sup> July 2023, 412 children aged 5-17 months were screened, and 51 were
excluded. A total of 361 children were enrolled in this study. In the first cohort, 119 were assigned to the
RH5.1/Matrix-M delayed third dose group, and 62 to the equivalent rabies control group. The second

Natama HM et al.

52	cohort included 120 children in the monthly RH5.1/Matrix-M group and 60 in the equivalent rabies
53	control group. The final vaccination was administered to all groups from 4 <sup>th</sup> to 21 <sup>st</sup> September 2023.
54	RH5.1/Matrix-M in both cohorts had a favourable safety profile and was well tolerated. Most adverse
55	events were mild, with the most common being local swelling and fever. No serious adverse events were
56	reported. A Cox regression model was used to analyse the primary endpoint of time to first episode of
57	clinical malaria, according to the primary case definition, within 14 days to 6 months post-third
58	vaccination. Comparing the RH5.1/Matrix-M delayed third dose regimen with the pooled control groups
59	resulted in vaccine efficacy of 55% (95% CI 20-75%; p=0.0071). The same analysis showed a vaccine
60	efficacy of 40% (95% CI -3-65%; p= $0.066$ ) when comparing the monthly regimen with the pooled
61	control groups. Participants vaccinated with RH5.1/Matrix-M in both cohorts showed high concentrations
62	of anti-RH5.1 serum IgG antibodies 14 days post-third vaccination, and the purified IgG showed high
63	levels of in vitro growth inhibition activity (GIA) against P. falciparum; these responses were higher in
64	RH5.1/Matrix-M vaccinees who received the delayed third dose, as opposed to monthly, regimen.
65	Interpretation
66	RH5.1/Matrix-M appears safe and highly immunogenic in African children and shows promising efficacy
67	against clinical malaria when given in a delayed third dose regimen. This trial remains ongoing to further
68	monitor efficacy over time.
69	Funding
70	The European and Developing Countries Clinical Trials Partnership; the UK Medical Research Council;
71	the National Institute for Health and Care Research Oxford Biomedical Research Centre; the Division of
72	Intramural Research, National Institute of Allergy and Infectious Diseases; the US Agency for

73 International Development; and the Wellcome Trust.

Natama HM et al.

# 74 Introduction

75	Malaria caused by the <i>Plasmodium falciparum</i> parasite continues to exert a heavy disease burden across
76	sub-Saharan Africa.1 However, two first-generation partially-effective pre-erythrocytic vaccines
77	(RTS,S/AS01 and R21/Matrix-M) are now recommended for malaria prevention in children using a 4-
78	dose schedule from around 5 months of age. These two vaccines are similar in design and target the liver-
79	invasive sporozoite. <sup>2,3</sup> However when this immunity fails or wanes over time, and sporozoites infect the
80	liver, blood-stage infection ensues with risk of clinical disease. Vaccination against the blood-stage
81	merozoite would thus provide a second line of defence. However, development of an effective blood-
82	stage vaccine has proved challenging, <sup>4</sup> with all prior phase 2b field efficacy trials reporting either no or
83	minimal efficacy, or evidence of strain-specific efficacy linked to target antigen polymorphism. <sup>5-9</sup>
84	
85	Identification of the reticulocyte-binding protein homologue 5 (RH5) as a vaccine target, <sup>10</sup> has since
86	transformed the blood-stage P. falciparum vaccine field. This merozoite protein forms an essential
87	interaction with basigin/CD147 on the human red blood cell during invasion <sup>11</sup> and, unlike previous
88	antigen targets, is almost completely conserved, likely explaining the human-species tropism of this
89	parasite. <sup>12</sup> We have previously demonstrated high-level efficacy of RH5-based vaccination in non-human
90	primates (NHPs) <sup>13</sup> and a significant reduction in parasite growth rate in UK adult vaccinees post-
91	challenge. <sup>14</sup> In both the NHP and human studies we observed a strong correlation between <i>in vivo</i>
92	reduction of parasite growth and <i>in vitro</i> growth inhibition activity (GIA), <sup>13,14</sup> since validated as a
93	mechanistic immune correlate in NHPs. <sup>15</sup> We have also reported promising safety and reactogenicity data
94	from four phase 1a/b trials of RH5-based vaccine candidates in 193 adults, children and infants in the UK
95	and Tanzania. <sup>14,16-18</sup> Notably, the RH5.1 protein <sup>19</sup> with Matrix-M adjuvant, in 5-17 month-old Tanzanian
96	children, gave the highest levels of human vaccine-induced GIA ever reported, exceeding the protective
97	threshold identified in the NHP model. <sup>13,18</sup> We therefore initiated a phase 2b trial (called "VAC091") of

- 98 this vaccine candidate in children aged 5-17 months in Nanoro, a seasonal malaria transmission setting in
- 99 Burkina Faso, to assess its protective efficacy against clinical malaria.

#### Natama HM et al.

#### 100 Methods

#### 101 Study design and participants

102 VAC091 is a double-blind, randomised, controlled phase 2b trial conducted by the Institut de Recherche

- 103 en Sciences de la Santé at the Clinical Research Unit of Nanoro, Burkina Faso and sponsored by the
- 104 University of Oxford. Participants aged 5-17 months were recruited at the Siglé trial site, located within
- 105 the Nanoro Health and Demographic Surveillance System (HDSS) catchment area. This covers 24
- 106 villages, with a population of over 63,000 inhabitants. Nanoro is an area where malaria transmission
- 107 occurs throughout the year, but with a marked peak during the rainy season (June to November).
- 108
- 109 Eligible participants were recruited into four groups (figure 1; appendix p 24). Groups 1 and 2 (first
- 110 cohort) received the delayed third-dose (0-1-5-month) regimen ("delayed regimen") of rabies or

111 RH5.1/Matrix-M vaccines, respectively. Groups 3 and 4 (second cohort) received these vaccines in a

112 "monthly regimen" (0-1-2-month). The third vaccination was given simultaneously across all four groups

- and completed part-way through the malaria season. Field workers collected data on indoor residual
- spraying (IRS) of households, insecticide treated net (ITN) use and if the nets were adequate (according

to if holes were present), and number of doses and months of seasonal malaria chemoprevention (SMC)

116 taken by the participant during the malaria transmission season.

117

After community sensitisation, a list of eligible children was drawn from the HDSS database, and parents or legally authorised guardians who expressed interest were invited to screening visits. Prior to the recruitment, parents or guardians of participants provided written or thumb-printed consent, which was verbally checked at each study visit. Inclusion criteria specified that participants should be aged 5-17 months at enrolment and aim to be living in the study area for the whole trial duration. Exclusion criteria included significant co-morbidities and participation in other malaria intervention studies and clinical trials. Further details are given in the appendix (pp 8-9).

125	The trial was approved by the National Ethical Committee of the Ministry of Health (Comité d'Ethique
126	pour la Recherche en Santé, reference number 2022-12-256), and the national regulatory authority,
127	Agence National de Régulation Pharmaceutique (reference 2023/0208/MSHP/SG/ANRP/DHEC/MIK), in
128	Burkina Faso. Ethical approval was granted in the UK by the Oxford Tropical Research Ethics Committee
129	(reference 3-23). This study is registered with ClinicalTrials.gov, NCT05790889.
130	
131	Randomisation and masking
132	Children aged 5-17 months were randomly assigned (1:2) to Groups 1 and 2 (delayed third-dose regimen)
133	in the first cohort and similarly to Groups 3 and 4 (monthly regimen) in the second cohort. A statistician
134	generated a random allocation list, using block randomisation with variable block sizes, and prepared and
135	sealed the envelopes using this list, which was then given to the pharmacist to assign to participants. Both
136	malaria and control vaccines were prepared by the pharmacist using the same type of syringe, and the
137	contents of the syringe were covered with an opaque label. The trial was double-blinded; participants,
138	their families, the central and local study teams and laboratory teams, were masked to group allocation.
139	Only the pharmacists preparing the vaccines and statisticians were unmasked to group allocation.
140	
141	Procedures
142	The RH5.1 soluble protein was originally produced according to Good Manufacturing Practice (GMP) by
143	the Clinical Biomanufacturing Facility in Oxford, UK. <sup>19</sup> A second batch was filled in 2021 under GMP by
144	a Contract Manufacturing Organisation in the UK and was used in this trial. A 10µg dose of RH5.1
145	protein was mixed with 50µg Matrix-M, a potent, saponin-based adjuvant manufactured by Novavax AB
146	(Uppsala, Sweden) and the Serum Institute of India Pvt. Ltd. (SIIPL), immediately before administration.
147	A rabies vaccine (Rabivax-S), manufactured by SIIPL, was the control vaccine. All vaccines were
148	administered intramuscularly into the thigh.
149	

#### Natama HM et al.

150	On the day of enrolment, a blood film was performed to check for <i>Plasmodium</i> spp. parasites. In the
151	absence of a fever $\geq$ 37.5°C and/or history of fever within the last 24 hours, participants proceeded to
152	vaccination, but if then found to be film-positive, they received treatment for malaria in accordance with
153	national guidelines. For each subsequent vaccination, participants were tested for malaria if they had a
154	fever of $\geq$ 37.5°C and/or history of fever within the last 24 hours. If their blood film was positive, they
155	were treated for malaria before being vaccinated upon recovery. After each vaccination, local and
156	systemic solicited adverse events (AEs) were collected for 7 days. Unsolicited AEs were collected for 28
157	days after vaccinations and classified according to MedDRA (version $27.0$ ). Severity and causality of
158	AEs were assessed using standardised methods (appendix pp 10-12, 25-26) and followed up until
159	resolution. Safety laboratory values were measured at 14 days post-second vaccination, day of third
160	vaccination (Groups 1 and 2 only) and two and six months post-third vaccination to look for deviations
161	from baseline. Serious adverse events (SAEs) are being recorded for the whole duration of the study. A
162	Data Safety Monitoring Board (DSMB) review was held after the first vaccination of the first 100
163	participants.
164	

Parents of participants were advised to attend the trial site or community health centres if their child had any illness or fever, for review and assessment for malaria. After the third vaccination, participants were also visited by field workers approximately every 30 days until 6 months after the third vaccination and a blood spot was taken for parasite quantification and genotyping. If they had a temperature of  $\geq 37.5^{\circ}$ C and/or history of fever within the last 24 hours, blood sampling was also performed for blood film microscopy to detect *Plasmodium* spp.

171

Anti-RH5.1 serum total IgG responses were measured by ELISA against full-length RH5 protein
(RH5.1), using standardised methodology as previously described.<sup>18</sup> Standardised GIA assays were

#### Natama HM et al.

performed by the GIA Reference Center, NIH, USA, using previously described methodology<sup>20</sup> (appendix
p 22-23).

176

#### 177 Outcomes

178 The co-primary objectives assessed were: i) safety and reactogenicity of RH5.1/Matrix-M, and ii)

179 protective efficacy of RH5.1/Matrix-M against clinical malaria from 14 days to 6 months post-third

180 vaccination. The primary case definition of clinical malaria was presence of an axillary temperature of

181  $\geq$  37.5°C and/or history of fever in the past 24 hours, and *P. falciparum* asexual parasite density >5000

182 parasites per  $\mu$ L. Secondary case definitions were presence of an axillary temperature of  $\geq$  37.5°C and/or

history of fever during the last 24 hours, and i) *P. falciparum* parasite density of >0 parasites per  $\mu$ L; or ii)

parasite density of >20,000 parasites per  $\mu$ L. Post-hoc analyses assessed additional case definitions with

parasite densities of >50,000 and >100,000 parasites per  $\mu$ L. Secondary objectives assessed i) protective

186 efficacy of RH5.1/Matrix-M against clinical malaria from 14 days to 3 months post-third vaccination; ii)

187 protective efficacy of RH5.1/Matrix-M against prevalent moderate or severe anaemia at 6 months post-

third vaccination; and iii) the humoral immunogenicity of RH5.1/Matrix-M. Analysis of other pre-

189 specified secondary objectives regarding the primary vaccination series remain in progress and will be

190 reported after the end of the trial (appendix pp 12-15).

191

#### 192 Statistical analysis

It was estimated that 104 children per arm would give 90% power to detect a 50% vaccine efficacy in either Group 2 or 4 compared to the pooled controls (Groups 1 and 3) if there were  $1 \cdot 2$  episodes of clinical malaria per child in the first 6 months of follow up in the control arm (appendix p 7). The rate of  $1 \cdot 2$  events per child comes from a study previously conducted in the same area.<sup>3</sup> 120 children per arm were recruited to allow for 15% loss to follow-up.

198

#### Natama HM et al.

199	For the co-primary endpoint of vaccine safety and reactogenicity, odds ratios comparing the proportion of
200	doses that resulted in solicited AEs were calculated using logistic regression. For the co-primary endpoint
201	of vaccine efficacy, Cox regression models were used to analyse time to first episode of clinical malaria
202	(as per the primary case definition) within 6 months post-third vaccination. Follow up time started 14
203	days post-third vaccination. Vaccine efficacy (VE) was calculated as 1 minus the hazard ratio (HR). The
204	secondary and additional case definitions of clinical malaria were analysed in the same way. A secondary
205	analysis of VE against all clinical malaria episodes was also carried out, using Cox regression models
206	with a robust standard error to account for multiple episodes. Episodes occurring within 14 days of a
207	previous episode were classed as the same event. For participants without an episode of clinical malaria,
208	their time was censored at the date of their withdrawal or the date of their 6-month blood sampling
209	(noting no deaths have occurred in this trial). A secondary analysis of time to first episode of clinical
210	malaria (analysed as per the primary endpoint) but restricted to episodes occurring within 3 months of the
211	third vaccination was also carried out. The primary comparisons were pre-specified as being between
212	Group 2 and the pooled control Groups 1 and 3, and between Group 4 and the pooled Groups 1 and 3,
213	with comparison of Groups 1 to 2 and 3 to 4 as a supplementary analysis. A secondary analysis adjusted
214	for confounding factors including total number of rounds of SMC received, ITN use (adequate or not) the
215	night before the screening visit, and age at randomisation (5-8 months, 9-12 months, or 13-17 months).
216	Event rates of malaria are also reported here, but for information only.

217

The primary analysis of VE was based on a per-protocol population, which included all participants who received three vaccinations correctly and within the pre-specified time period. Secondary analyses included the intention-to-treat population of any child who received at least the first dose of vaccine and remained in the site at the start of the follow-up period (2 weeks post their third dose).

222

223	Assays to measure in vitro P. falciparum GIA and serum anti-RH5.1 IgG responses were conducted on
224	blood samples taken at baseline (screening) and at day 14 post-third vaccination. GIA data were
225	expressed as percentages and compared between the combined control groups and each RH5.1/Matrix-M
226	vaccine group, and between the two RH5.1/Matrix-M vaccine groups. The measure of effect was the
227	difference in mean percentage GIA, with inference done using the bootstrap method. Serum anti-RH5.1
228	IgG concentrations measured by ELISA were log10-transformed and the same between-arm comparisons
229	performed by linear regression.
230	
231	All statistical analyses were performed by independent statisticians using Stata, version 18.
232	
233	Role of the funding source
234	The funder of the study had no role in study design, data collection, data analysis, data interpretation, or
235	writing of the report.

Natama HM et al.

# 236 **Results**

237	From 6 <sup>th</sup> to 13 <sup>th</sup> April 2023, 208 children aged 5-17 months were screened, and from 3 <sup>rd</sup> to 7 <sup>th</sup> July 2023, a
238	further 204 children aged 5-17 months were screened (figure 1). Fifty-one were excluded and 361
239	enrolled across two cohorts. In the first cohort, 119 children were allocated to receive RH5.1/Matrix-M in
240	a delayed third-dose regimen (Group 2) and 62 children allocated to rabies vaccination in the same
241	regimen (Group 1). In the second cohort, 120 children were allocated to RH5.1/Matrix-M in a monthly
242	regimen (Group 4) and 60 children allocated to receive rabies vaccination in the same regimen (Group 3).
243	The final vaccination of the primary series was administered contemporaneously across both cohorts from
244	4 <sup>th</sup> to 21 <sup>st</sup> September 2023. Twenty-two participants received fewer than three vaccinations, and one
245	participant in Group 3 who received three vaccinations had an interval of less than 21 days between the
246	second and third vaccine doses, so 338 participants were included in the per-protocol analysis at six
247	months post-third vaccination.
248	
249	Baseline characteristics were similar across the four study groups, with the overall mean age at screening
250	of 10.5 months (SD 3.6), and 177 (52.4%) of the enrolled participants being female (appendix p 31). Of
251	the 361 participants, 290 (85.8%) slept under an adequate ITN the night before screening, and 333
252	(98.5%) received at least one round of SMC. However, only 8 $(2.4%)$ of 361 participants lived in a house
253	which had received IRS with insecticide in the past year.
254	
255	Analysis of the primary endpoint of time to first episode of clinical malaria (as per the primary case
256	definition) within 14 days to 6 months post-third vaccination, using a Cox regression model to compare
257	the RH5.1/Matrix-M delayed third dose regimen with the pooled control groups, resulted in VE of 55%
258	(95% CI 20-75%; p=0.0071); the same analysis showed a VE of 40% (95% CI -3-65%; p=0.066) when
259	comparing the monthly regimen with the pooled control groups (table 1 and figure 2A).

260

Natama HM et al.

261	During this primary objective study period (within 14 days to 6 months post-third vaccination) a first
262	episode of clinical malaria occurred in 17 of 114 participants (14.9%) in the delayed RH5.1/Matrix-M
263	group (event rate 0.09/100 child days); 22 of 112 participants (19.6%) in the monthly RH5.1/Matrix-M
264	group (event rate 0.12/100 child days); and 33 of 112 participants (29.5%) in the pooled rabies control
265	groups (event rate $0.21/100$ child days) (table 1). In total, 72 of 338 participants (21.3%) had at least one
266	episode of clinical malaria according to the primary case definition however, of these, 10 also had more
267	than one episode. In a secondary analysis, VE against all clinical malaria episodes up to 6 months (as per
268	the primary case definition), analysed using Cox regression models, was 56% (95% CI 24-74%;
269	p=0.0035) for the delayed and 40% (95% CI 1-64%; p=0.045) for the monthly RH5.1/Matrix-M regimen
270	(appendix pp 34-35).
271	
272	As a secondary objective, we also analysed time to first episode of clinical malaria (as per the primary
273	case definition) within 14 days to 3 months post-third vaccination using a Cox regression model. Here,
274	a VE of 56% (95% CI 21-76%; p=0.0062) in the delayed regimen and 52% (95% CI 13-73%; p=0.015)

in the monthly regimen was observed when comparing with the pooled control groups (appendix pp 44-

45). Here, 65 of 338 participants (19.2%) had at least one episode of malaria according to the primary

277 case definition during this period.

278

We also analysed the time to first episode of clinical malaria, using a Cox regression model, according to secondary case definitions of clinical malaria during the 6-month period with i) a parasitaemia >0 per  $\mu$ L; here VE of 44% [95% CI 8-66%; p=0.023] was observed in the delayed group and 8% [95% CI -44-41%; p=0.73] in the monthly group; and ii) a parasitaemia >20,000 per  $\mu$ L; here VE of 69% [95% CI 35-85%; p=0.0017] was observed in the delayed group and 47% [95% CI 3-71%; p= 0.041] in the monthly group (table 1, figure 2B,C). In light of these results, additional post-hoc analyses were performed for case definitions of clinical malaria with i) parasitaemia >50,000 per  $\mu$ L; here VE of 81% [95% CI 44-94%;

286	p=0.0026] was observed in the delayed group and 90% [95% CI 58-98%; $p=0.0017$ ] in the monthly
287	group; and ii) parasitaemia >100,000 per $\mu$ L; here VE of 83% [95% CI 23-96%; p=0.021] was observed
288	in the delayed group and 91% [95% CI 33-99%; p=0.019] in the monthly group (table 1, figure 2D,E).
289	Secondary analyses of all efficacy endpoints for the intention-to-treat population showed similar results to
290	those for the per-protocol population (appendix pp 38-43, 46).
291	
292	There were no SAEs, AEs of special interest (AESIs) or suspected unexpected serious adverse reactions
293	(SUSARs) reported out to 6 months post-third vaccination. There were no safety concerns raised by the
294	DSMB following review of 7 days' data after vaccination of the first 100 participants, and no further
295	safety reviews were required. Swelling was the most common local solicited AE, reported after 24/696
296	(3.4%) RH5.1/Matrix-M vaccinations, with significantly more swelling reported in the delayed
297	RH5.1/Matrix-M group compared to the combined control groups (odds ratio [OR] 11.2, 95% CI 2.6-
298	49.4, p=0.0014). The most common systemic solicited AE was fever, reported after 97/696 (13.9%)
299	RH5.1/Matrix-M vaccinations and $5/349 (1.4\%)$ rabies vaccinations (table 2). There were significantly
300	more fevers in both the delayed (OR 14·1, 95% CI 5·3-37·1, p<0·0001) and monthly (OR 9·7, 95% CI 5·3-37·1, p<0·0001) and mont
301	3.7-25.9, p<0.0001) RH5.1/Matrix-M vaccination groups as compared to the control groups. No
302	participants experienced febrile convulsions. The majority of solicited AEs were mild to moderate in
303	severity. Four participants (1.7%) were reported to have severe pain following RH5.1/Matrix-M
304	vaccination, compared to four $(3.3\%)$ following rabies vaccination. Three participants $(1.3\%)$ were
305	reported to have severe fever and one participant $(0.4\%)$ reported to have severe loss of appetite
306	following RH5.1/Matrix-M vaccination (appendix pp 47-48).
307	
308	For unsolicited AEs, 39 MedDRA terms were assigned in the 28 days following each of the three
309	vaccinations and there were no significant differences in the number of events per group (appendix pp 49-
310	52). All were classified as unrelated to the vaccines, with the exception of a single episode of moderate

311	fever in the delayed third-dose group within 28 days of vaccination. There were no cases of severe
312	anaemia (haemoglobin $<5.0$ g/L), no participants requiring blood transfusion, and no significant
313	differences in the frequency of moderate anaemia (haemoglobin $<8 \cdot 0$ g/L) between the groups (appendix
314	53). There were no cases of severe malaria in any participant in the 6 months post-third vaccination.
315	
316	At baseline, almost all participants showed background level anti-RH5.1 serum IgG antibody responses.
317	At 14 days post-third vaccination, responses remained comparable to baseline in the combined rabies
318	vaccine control groups. In contrast, high responses were seen in the delayed regimen RH5.1/Matrix-M
319	group (geometric mean anti-RH5.1 IgG concentration 837µg/mL; inter-quartile range [IQR] 326-2200);
320	these were significantly higher as compared to the monthly regimen group (geometric mean 626µg/mL;
321	IQR 222-1455; p=0.0006) (figure 3A). In vitro functional anti-parasitic activity was assessed by the GIA
322	assay at a total purified IgG concentration of 2.5 mg/mL at 14 days post-third vaccination. Samples from
323	control participants showed negligible GIA (<20%), apart from three participants who had GIA of >50%.
324	Mean GIA in the delayed regimen RH5.1/Matrix-M group was 79.0% (standard deviation [SD] 14.3),
325	significantly higher than the mean GIA in the monthly group of $74 \cdot 2\%$ (SD 15.9; p=0.016) (figure 3B,
326	appendix pp 54-55).

We report that the standalone blood-stage vaccine candidate RH5.1/Matrix-M, delivered in a delayed

Natama HM et al.

#### 327 Discussion

328

329 third dose (0-1-5 month) regimen, shows significant efficacy of 55% (95% CI 20-75%) against clinical 330 malaria in the target population of African children over 6 months' follow-up. The vaccine was also well-331 tolerated and no SAEs were reported out to 6-months following the third vaccination. Data now reported 332 for a total of 109 adults, 305 children and 18 infants vaccinated with RH5-based vaccines in the UK, Tanzania and Burkina Faso<sup>14,16-18</sup> all show similar safety and tolerability profiles, whilst Matrix-M 333 adjuvant is now licensed in vaccines for malaria and Covid-19.<sup>3,21</sup> On-going phase 1/2 trials continue to 334 335 monitor the safety of RH5.1/Matrix-M vaccination. 336 337 Here we studied RH5.1/Matrix-M efficacy for the first time in an area of seasonal malaria transmission, 338 with vaccinations completing part-way through the malaria season. Previously published field efficacy 339 trials of P. falciparum blood-stage vaccine candidates, targeting a variety of antigens including AMA1, 340 MSP1, MSP2, GLURP, MSP3 and RESA, all yielded disappointing results, reporting either no or 341 minimal clinical efficacy, or in some cases evidence of strain-specific efficacy linked to target antigen polymorphism.<sup>5-9</sup> Given these studies were performed over the last 25 years in different settings with 342 343 different transmission patterns and in children of different age ranges, it is not possible to directly 344 compare with our study. However, our results demonstrate that a standalone blood-stage vaccine can 345 achieve significant efficacy against clinical malaria in 5-17 month old children, in line with the approved 346 age range for use of the pre-erythrocytic vaccines RTS,S/AS01 and R21/Matrix-M, and now enabling 347 future assessment of combination malaria vaccine strategies targeting two stages of the parasite's lifecycle. Indeed, a second-generation multi-stage paediatric vaccination strategy offers hope for higher 348 349 and more durable efficacy against clinical malaria, especially if the pre-erythrocytic and blood-stage 350 components act additively, or even synergistically.

#### Natama HM et al.

351	SMC was given to children in the study area as part of a programme by local health services, as per
352	national policy recommendation, but coverage was suboptimal. Our study documented SMC uptake, but
353	did not deliver any further SMC. It will be important in the future to test RH5.1/Matrix-M efficacy in
354	settings where there is no SMC, and to also determine in seasonal settings whether combination of blood-
355	stage and pre-erythrocytic vaccines can achieve a better outcome (than a pre-erythrocytic vaccine alone)
356	as indicated by studies of RTS.S/AS01 and SMC. <sup>22</sup>

357

Our study was not powered to show a difference in VE between the 0-1-2 and 0-1-5-month delivery 358 359 regimens with RH5.1/Matrix-M. However, the VE for the 0-1-5 month regimen was higher than for the 360 0-1-2 month regimen, and this is consistent with the 0-1-5-month regimen inducing higher IgG 361 concentrations and GIA. The difference in VE was larger at 6 months than 3 months, suggesting the 0-1-362 5-month regimen may offer more durable protection. Previous trials of RTS, S/AS01 reported improved 363 efficacy against malaria challenge in healthy US adults when using a 0-1-7-month regimen with antigen and adjuvant fractionated for the delayed third dose (as opposed to 0-1-2-month dosing),<sup>23</sup> however, this 364 did not translate to improved field efficacy in 5-17 month old children.<sup>24</sup>. In line with these observations, 365 366 our previous phase 1b trial data with RH5.1/Matrix-M in Tanzanian children suggested that a delayed (full) third dose, as opposed to monthly dosing or a delayed fractional third dose, may induce more 367 robust and durable antibody responses.<sup>18</sup> On-going analyses in this trial will thus continue to investigate 368 369 whether the delayed third dose regimen induces more durable immunity in contrast to monthly dosing. 370

Notably, our secondary and post-hoc analyses showed lower VE (as compared to the primary endpoint)
when we used the secondary clinical malaria case definition of any parasitaemia (>0 parasites/µL) but
increasingly improved efficacy when we used secondary or additional malaria case definitions with a
higher parasitaemia cut-off of >20,000, >50,000 or >100,000 parasites/µL. The delayed third dose
RH5.1/Matrix-M regimen showed significant efficacy against all definitions, whilst the monthly regimen

#### Natama HM et al.

376	only reached significance at the higher cut-offs consistent with the more modest performance of this
377	regimen but nonetheless suggesting biological effect. These data appear in line with research in animal
378	vaccination and challenge models of malaria, <sup>13</sup> whereby blood-stage malaria vaccines can reduce peak
379	parasitaemia. This would also not be expected to occur with pre-erythrocytic vaccines; indeed, post-hoc
380	analysis of data from the phase 3 trial of R21/Matrix-M3 showed almost identical VE for all the cut-off
381	levels of parasitaemia analysed here (Adrian Hill, personal communication). Consequently, our data
382	show that RH5.1/Matrix-M can partially protect against clinical malaria but can also reduce blood-stage
383	parasitaemia in clinical cases. This may have implications for prevention of severe or life-threatening
384	disease in the real-world setting when pre-erythrocytic- and/or blood-stage vaccine-induced immunity to
385	clinical malaria fails or wanes.
386	
387	Solicited AE rates observed with RH5.1/Matrix-M compare favourably to those seen in the phase 3 trials
388	of R21/Matrix-M and RTS,S/AS01. <sup>2,3</sup> Swelling at the injection site, the most common local solicited AE
389	in this trial, occurred following 4% of vaccinations with R21/Matrix-M and 10% with RTS,S/AS01, in
390	comparison to 3% with RH5.1/Matrix-M. For R21/Matrix-M and RTS,S/AS01, the most common local
391	solicited AE was pain, occurring following 19% and 12% of vaccinations respectively, in comparison to
392	3% with RH5.1/Matrix-M. Fever was the most common systemic solicited AE with all vaccines,
393	occurring following 47% of vaccinations with R21/Matrix-M and 31% with RTS,S/AS01, in comparison
394	to 14% with RH5.1/Matrix-M.
395	
396	The absence of RH5 serum antibody responses at baseline or in the control groups at 14 days post-third
397	vaccination is consistent with the known sero-epidemiology and sequence conservation of RH5,

398 suggesting this antigen is not a dominant target of naturally-acquired malaria immunity.<sup>10,16,25</sup> In contrast,

the RH5.1/Matrix-M vaccine candidate was highly immunogenic for functional anti-RH5.1 serum IgG

400 antibody across both dosing regimens, with the delayed third dose regimen showing small but significant

401	improvements in the ELISA and GIA responses (as compared to the monthly regimen) 14 days post-third
402	vaccination, in line with our data seen in Tanzanian children in the RH5.1/Matrix-M phase 1b study. <sup>18</sup>
403	The mean GIA observed in both RH5.1/Matrix-M groups, and over 80% of individual children, at this
404	timepoint also exceeded 60% GIA measured at $2.5 \text{ mg/mL}$ total IgG (appendix p 54-55) – a threshold
405	level we previously reported as required for protection following RH5 vaccination and P. falciparum
406	blood-stage challenge in Aotus monkeys. <sup>13,15</sup> These data are thus consistent with both RH5.1/Matrix-M
407	regimens showing significant efficacy against clinical malaria in the first 3 months post-third
408	vaccination. Analysis of the kinetic of both groups' immune responses beyond this peak post-vaccination
409	timepoint are ongoing, but the efficacy data after 3 months suggest that differences may be seen with
410	respect to serum antibody durability and/or the possibility for natural boosting of the vaccine-induced
411	response.
412	
413	This study has limitations, including the completion of vaccine doses part-way through the malaria
414	season. It is possible that VE might be different if administered earlier, i.e. with the primary vaccination
415	series (all three doses) being completed prior to the season. Another limitation that comes from
416	administering the vaccine part-way through the malaria season is that there was insufficient follow up
417	time to observe many children having multiple episodes. It is possible that naturally-acquired immunity
418	may interact with vaccine-induced immunity, protecting children from subsequent episodes, but the
419	current analysis was unable to investigate this. Nonetheless, follow-up of the VAC091 trial is continuing
420	to determine efficacy at 12 months post-third vaccination, and to assess the durability of the vaccine-
421	induced immune response and the potential impact of natural malaria exposure. We will also administer a
422	fourth (booster) dose of vaccine at 12 months to Groups 1-4 to enable efficacy monitoring over a second
423	year of follow-up. We also limited the age range of participants in this trial to 5-17 months, to align with
424	earlier studies of RTS,S/AS01 and R21/Matrix-M. A wider age range, inclusive of younger infants and
425	older children, will be covered in future trials. We have not yet assessed RH5.1/Matrix-M delivered in an

- 426 age-based (non-seasonal) administration schedule, or in sites with lower or higher levels of perennial
- 427 malaria transmission as compared to the seasonal setting in Nanoro; this will be addressed in future
- 428 studies. We have also not yet formally analysed our immunological datasets for correlates of protection;
- 429 this, along with assessment for any evidence of *P. falciparum* strain-selection in vaccinees versus
- 430 controls, remains the focus of ongoing work.

Natama HM et al.

# 431 **Contributors**

- 432 JS, SES, SJD and AMM conceived the trial. HT was the trial principal investigator, AMM the chief
- 433 investigator, and SJD the senior laboratory investigator. HMN, JS, AS, SD, OT, TR, FO, EO, KCSD,
- 434 NAK, ZMJC, MK, MAB, FK, HS, CMN, DP, AD, CAL, KM, SES, HT and AMM contributed to the
- 435 implementation of the study and data collection. SS and JB analysed data and completed statistical
- 436 analysis. HMN, SD, JSC, AML, KS and RR performed project management. LDWK, US and KS assisted
- 437 with vaccine provision. HMN, JS, KM, SES, SJD, HT and AMM interpreted data, contributed to writing
- 438 the manuscript and have accessed and verified the data.
- 439

# 440 **Declaration of interests**

441 LDWK and SJD are named inventors on patent applications relating to RH5 malaria vaccines. AMM has

442 an immediate family member who is an inventor on patent applications relating to RH5 malaria vaccines.

443 US is an employee of Serum Institute of India Pvt. Ltd., manufacturer of R21/Matrix-M vaccine. All other

444 authors declare no competing interests.

445

#### 446 Data sharing

Data associated with this study are present in the paper or appendix and will be available after the end of the study upon reasonable request that should be directed to the corresponding author. Proposals will be reviewed and approved by the Sponsor, Chief Investigator, and collaborators. After approval of a proposal, data can be shared through a secure online platform after signing a data access agreement. Any

451 shared data will be de-identified.

Natama HM et al.

# 452 Acknowledgments

453	We thank all the trial participants and their parents, and the independent DSMB for overseeing the trial.
454	This work was funded in part by the European and Developing Countries Clinical Trials Partnership
455	(EDCTP) Multi-Stage Malaria Vaccine Consortium (MMVC) [RIA2016V-1649-MMVC]; a Wellcome
456	Trust Translation Award [205981/Z/17/Z], the UK Medical Research Council [MR/K025554/1 and
457	MR/V038427/1, the latter UK-funded award is carried out in the frame of the Global Health EDCTP3
458	Joint Undertaking]; the National Institute for Health and Care Research (NIHR) Oxford Biomedical
459	Research Centre (BRC), the views expressed are those of the authors and not necessarily those of the
460	NHS, the NIHR, or the Department of Health; Matrix-M adjuvant and rabies vaccine was supplied by
461	SIIPL; the GIA work was supported by the Division of Intramural Research, National Institute of Allergy
462	and Infectious Diseases (NIAID) and by an Interagency Agreement [AID-GH-T-15-00001] between the
463	United States Agency for International Development (USAID) Malaria Vaccine Development Program
464	(MVDP) and NIAID. The findings and conclusions are those of the authors and do not necessarily
465	represent the official position of USAID. CMN held a Wellcome Trust Sir Henry Wellcome Postdoctoral
466	Fellowship [209200/Z/17/Z]. SJD is a Jenner Investigator. All authors had full access to all the data in the
467	study and had final responsibility for the decision to submit for publication.

Natama HM et al.

## 468 **References**

469 World Health Organization. World Malaria Report; 2023. 1. 2. 470 Rts SCTP. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in 471 infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 472 2015; 386(9988): 31-45. 473 Datoo MS, Dicko A, Tinto H, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-3. 474 M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 2024; 403(10426): 475 533-44. 476 4. Draper SJ, Sack BK, King CR, et al. Malaria Vaccines: Recent Advances and New Horizons. Cell 477 Host Microbe 2018: 24(1): 43-56. 478 5. Sirima SB, Mordmuller B, Milligan P, et al. A phase 2b randomized, controlled trial of the 479 efficacy of the GMZ2 malaria vaccine in African children. Vaccine 2016; 34(38): 4536-42. 480 Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine. 6. 481 *N Engl J Med* 2011; **365**(11): 1004-13. 482 Sagara I, Dicko A, Ellis RD, et al. A randomized controlled phase 2 trial of the blood stage 7. 483 AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009; 27(23): 3090-8. 484 Ogutu BR, Apollo OJ, McKinney D, et al. Blood stage malaria vaccine eliciting high antigen-8. 485 specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 486 2009; **4**(3): e4708. 487 Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces 9. 488 Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial 489 in Papua New Guinea. J Infect Dis 2002; 185(6): 820-7. 490 Douglas AD, Williams AR, Illingworth JJ, et al. The blood-stage malaria antigen PfRH5 is 10. 491 susceptible to vaccine-inducible cross-strain neutralizing antibody. *Nat Commun* 2011; 2: 601. 492 11. Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte 493 invasion by Plasmodium falciparum. Nature 2011; 480(7378): 534-7. Galaway F, Yu R, Constantinou A, Prugnolle F, Wright GJ. Resurrection of the ancestral RH5 494 12. 495 invasion ligand provides a molecular explanation for the origin of P. falciparum malaria in humans. PLoS 496 *Biol* 2019; **17**(10): e3000490. 497 13. Douglas AD, Baldeviano GC, Lucas CM, et al. A PfRH5-Based Vaccine Is Efficacious against 498 Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. Cell Host 499 *Microbe* 2015; **17**(1): 130-9. 500 14. Minassian AM, Silk SE, Barrett JR, et al. Reduced blood-stage malaria growth and immune 501 correlates in humans following RH5 vaccination. Med 2021; 2(6): 701-19. 502 Douglas AD, Baldeviano GC, Jin J, et al. A defined mechanistic correlate of protection against 15. 503 Plasmodium falciparum malaria in non-human primates. Nat Commun 2019; 10(1): 1953. 504 Payne RO, Silk SE, Elias SC, et al. Human vaccination against RH5 induces neutralizing 16. 505 antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight 2017; 2(21): 96381. 506 Silk SE, Kalinga WF, Mtaka IM, et al. Superior antibody immunogenicity of a viral-vectored 17. 507 RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. Med 2023; 4(10): 668-86. 508 18. Silk SE, Kalinga WF, Salkeld J, et al. Blood-stage malaria vaccine candidate RH5.1/Matrix-M in 509 healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial. Lancet Infect Dis 2024; 24(10): 1105-17. 510 511 Jin J, Tarrant RD, Bolam EJ, et al. Production, quality control, stability, and potency of cGMP-19. 512 produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells. NPJ Vaccines 513 2018; 3: 32. 514 Malkin EM, Diemert DJ, McArthur JH, et al. Phase 1 clinical trial of apical membrane antigen 1: 20. 515 an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005; 73(6): 3677-85.

Natama HM et al.

- 516 21. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19
- 517 Vaccine. N Engl J Med 2021; **385**(13): 1172-83.
- 518 22. Chandramohan D, Zongo I, Sagara I, et al. Seasonal Malaria Vaccination with or without
- 519 Seasonal Malaria Chemoprevention. *N Engl J Med* 2021; **385**(11): 1005-17.
- 520 23. Regules JA, Cicatelli SB, Bennett JW, et al. Fractional Third and Fourth Dose of RTS, S/AS01
- 521 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and
- 522 Immunogenicity Study. J Infect Dis 2016; **214**(5): 762-71.
- 523 24. Samuels AM, Ansong D, Kariuki SK, et al. Efficacy of RTS, S/AS01(E) malaria vaccine
- administered according to different full, fractional, and delayed third or early fourth dose regimens in
- 525 children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial.
- 526 *Lancet Infect Dis* 2022; **22**(9): 1329-42.
- 527 25. Osier FH, Mackinnon MJ, Crosnier C, et al. New antigens for a multicomponent blood-stage
- 528 malaria vaccine. *Sci Transl Med* 2014; **6**(247): 247ra102.

529

#### Natama HM et al.

# 530 Figure Legends

#### 531 **Figure 1: Trial profile.**

532 Participants allocated to the delayed regimen received vaccinations at 0-1-5 months. Participants allocated

to the monthly regimen received vaccinations at 0-1-2 months. Participants were aged 5-17 months at

534 enrolment (first day of vaccination). MM = Matrix-M.

535

# Table 1: Analysis of time to first episode of clinical malaria from 14 days to 6 months postthird vaccination.

538 Cox regression models were used to analyse the primary endpoint of time to first episode of clinical

539 malaria based on the per-protocol population at the 6-month analysis timepoint. Clinical malaria is

540 defined as measured axillary temperature  $\geq$  37.5°C and/or reported history of fever within the last 24

541 hours, and *P. falciparum* asexual parasitaemia concentration according to each case definition. Vaccine

542 Efficacy = 1 – hazard ratio. 95% CI = 95% Confidence Interval. \* Secondary analysis adjusted vaccine

543 efficacy: includes covariates of total number of rounds of SMC received, ITN use (adequate or not) the

night before the screening visit, and age categories 5-8 months, 9-12 months, 13-17 months. Excludes 5

children with missing data on covariates: 1 in the Delayed Rabies arm, 3 in the Delayed RH5.1/Matrix-M

arm and 1 in the Monthly RH5.1/Matrix-M arm. \*\* Event rate per 100 days (where event is the first

547 episode of clinical malaria) is also reported for information only, calculated as: (the number of events /

548 [child days/100]).

549

# 550 Figure 2: Kaplan-Meier curves showing time to first episode of clinical malaria from 14

# 551 days to 6 months post-third vaccination.

552 The primary analysis was based on the per-protocol population. (A) Primary case definition of clinical

553 malaria with parasitaemia >5000 parasites/µL. (B) Secondary case definition of clinical malaria with

#### Natama HM et al.

554	parasitaemia >0	parasites/µL,	, or (C) > 20,000	parasites/µL. (	<b>(D)</b> Additional	case definition of clinical
-----	-----------------	---------------	-------------------	-----------------	-----------------------	-----------------------------

- 555 malaria with parasitaemia >50,000 parasites/ $\mu$ L, or (E) >100,000 parasites/ $\mu$ L.
- 556

## 557 Table 2: Solicited AEs within 7 days of vaccine dose across all groups.

- 558 By number of doses (n and (%)). Includes all children in the intention-to-treat sample who received at
- least one dose of vaccine. N = number of participants who received each dose.

560

# 561 **Figure 3: RH5.1/Matrix-M humoral immunogenicity.**

562 Immunological outcomes in study participants in the per-protocol sample. (A) Anti-RH5.1 serum IgG

responses by vaccination group at baseline (screening) and day 14 post-vaccine dose three. Individual

- anti-RH5.1 total IgG antibody concentrations (dots) and geometric mean with 95% CIs (diamonds with
- black bars). N=111 children for the Rabies (Rabivax-S) delayed and monthly groups combined, N=113
- 566 for the Delayed RH5.1/Matrix-M group, and N=107 for the Monthly RH5.1/Matrix-M group. (**B**)
- 567 Percentage *in vitro* GIA of 3D7 clone *P. falciparum* parasites by vaccination group, using 2.5mg/mL total
- 568 IgG purified from serum taken on day 14 post-vaccine dose three. Individual percentage inhibition figures
- 569 (small dots) and median and interquartile range (large dots and black bars). N=97 children for the Rabies
- 570 (Rabivax-S) delayed and monthly groups combined, N=113 children for the Delayed RH5.1/Matrix-M

571 group, and N=108 for the Monthly RH5.1/Matrix-M group.

# Figure 1: Trial profile



medRxiv preprint doi: https://doi.org/10.1101/2024.10.15.24315473; this version posted October 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. Table 1: Analysis of time to first episode of clinical malaria from 14 days to 6 months post-third

vaccination.

Groups	N	Event rate per 100 days **	VACCINE EFFICACY (95% CI)	р	VACCINE EFFICACY (95% CI) [adjusted*]	p [adjusted]		
Primary Case Definition (parasitaemia >5000 parasites/µL)								
Rabies controls (combined)	112	0.21 (33/156.3)	1		1			
Delayed RH5.1/Matrix-M	114	0.09 (17/185.0)	0.55 (0.20, 0.75)	0.0071	0.57 (0.23, 0.77)	0.0051		
Monthly RH5.1/Matrix-M	112	0.12 (22/176.4)	0.40 (-0.03, 0.65)	0.0657	0.42 (-0.01, 0.66)	0.0525		
Secondary Case Definition (par	asitaem	ia > <b>0</b> parasites/µL)						
Rabies controls (combined)	112	0.26 (39/147.4)	1		1			
Delayed RH5.1/Matrix-M	114	0.15 (26/176.5)	0.44 (0.08, 0.66)	0.0226	0.44 (0.06, 0.66)	0.0283		
Monthly RH5.1/Matrix-M	112	0.25 (39/158.9)	0.08 (-0.44, 0.41)	0.7280	0.07 (-0.46, 0.41)	0.7489		
Secondary Case Definition (par	asitaem	ia > <b>20,000</b> parasites/µ	L)					
Rabies controls (combined)	112	0.17 (28/164.3)	1		1			
Delayed RH5.1/Matrix-M	114	0.05 (10/194.5)	0.69 (0.35, 0.85)	0.0017	0.68 (0.33, 0.85)	0.0024		
Monthly RH5.1/Matrix-M	112	0.09 (16/183.0)	0.47 (0.03, 0.71)	0.0410	0.52 (0.12, 0.74)	0.0186		
Additional Case Definition (par	asitaem	ia > <b>50,000</b> parasites/µ	L)					
Rabies controls (combined)	112	0.11 (19/178.7)	1		1			
Delayed RH5.1/Matrix-M	114	0.02 (4/203.4)	0.81 (0.44, 0.94)	0.0026	0.79 (0.38, 0.93)	0.0047		
Monthly RH5.1/Matrix-M	112	0.01 (2/201.9)	0.90 (0.58, 0.98)	0.0017	0.91 (0.62, 0.98)	0.0011		
Additional Case Definition (par	Additional Case Definition (parasitaemia >100,000 parasites/µL)							
Rabies controls (combined)	112	0.06 (11/190.2)	1		1			
Delayed RH5.1/Matrix-M	114	0.01 (2/206.3)	0.83 (0.23, 0.96)	0.0213	0.82 (0.18, 0.96)	0.0271		
Monthly RH5.1/Matrix-M	112	0.00 (1/203.1)	0.91 (0.33, 0.99)	0.0193	0.92 (0.39, 0.99)	0.0148		

medRxiv preprint doi: https://doi.org/10.1101/2024.10.15.24315473; this version posted October 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. Figure 2: Kaplan-Meier curves showing time to first episode of clinical malaria from 14 days to

6 months post-third vaccination.



medRxiv preprint doi: https://doi.org/10.1101/2024.10.15.24315473; this version posted October 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2: Solicited AEs within 7 days of vaccine dose across all groups.

Adverse event	Dose number	Delayed Rabies Control	Delayed RH5.1/Matrix-M	Monthly Rabies Control	Monthly RH5.1/Matrix-M
Ν	Dose 1	62	119	60	120
N	Dose 2	61	118	60	119
N	Dose 3	55	114	57	113
Local events					
	Dose 1	3 (5.0)	5 (4.2)	1 (1.7)	0 (0.0)
Pain	Dose 2	1 (1.6)	6 (5.1)	0 (0.0)	1 (0.8)
	Dose 3	0 (0.0)	3 (2.6)	1 (1.8)	3 (2.7)
	Dose 1	1 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling	Dose 2	0 (0.0)	17 (14·4)	1 (1.7)	5 (4.2)
	Dose 3	0 (0.0)	2 (1.8)	0 (0.0)	0 (0.0)
	Dose 1	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)
Redness	Dose 2	0 (0.0)	1 (0.8)	0 (0.0)	2 (1.7)
	Dose 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Dose 1	2 (3.2)	3 (2.5)	0 (0.0)	0 (0.0)
Warmth	Dose 2	0 (0.0)	2 (1.7)	0 (0.0)	4 (3.4)
	Dose 3	1 (1.8)	1 (0.9)	0 (0.0)	1 (0.9)
Systemic eve	ents				
	Dose 1	1 (1.6)	6 (5.0)	0 (0.0)	4 (3.3)
Fever	Dose 2	2 (3.3)	27 (22.9)	1 (1.7)	26 (21.8)
	Dose 3	1 (1.8)	21 (18·4)	0 (0.0)	13 (11.5)
	Dose 1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Irritable	Dose 2	1 (1.6)	2 (1.7)	1 (1.7)	0 (0.0)
	Dose 3	1 (1.8)	1 (0.9)	1 (1.8)	1 (0.9)
	Dose 1	0 (0.0)	4 (3.4)	1 (1.7)	0 (0.0)
Drowsiness	Dose 2	0 (0.0)	3 (2.5)	0 (0.0)	1 (0.8)
	Dose 3	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.9)
_	Dose 1	1 (1.6)	2 (1.7)	0 (0.0)	0 (0.0)
Loss of	Dose 2	2 (3.3)	4 (3.4)	1 (1.7)	1 (0.8)
appente	Dose 3	1 (1.8)	1 (0.9)	0 (0.0)	1 (0.9)

medRxiv preprint doi: https://doi.org/10.1101/2024.10.15.24315473; this version posted October 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 3: RH5.1/Matrix-M humoral immunogenicity.

